A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD

NCT00793923 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Exudative Age-Related Macular Degeneration

Interventions

DRUG: ranibizumab and dexamethasone
DRUG: Ranibizumab

Sponsor

Subhransu K. Ray, M.D., Ph.D.

Collaborators

[object Object]